NCT01379937 - A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children | Biotech Hunter

Enrollment

520

Participants

Timeline

Start Date

July 28, 2011

Primary Completion Date

August 2, 2012

Study Completion Date

October 5, 2012

Conditions

Influenza

Interventions

BIOLOGICAL

Influenza vaccine GSK1562902A Formulation 1

Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group

BIOLOGICAL

Influenza vaccine GSK1562902A Formulation 2

Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group

BIOLOGICAL

Havrix™

Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group

BIOLOGICAL

Havrix™ Junior

Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group

Trial Locations (2)

1113

GSK Investigational Site, Quezon City

1781

GSK Investigational Site, Alabang, Muntinlupa